The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

KARMINOMYCIN     (9R)-7-(4-amino-5-hydroxy-6- methyl-oxan-2...

Synonyms: CCRIS 961, AC1L1ZFE, LS-86968, 39472-31-6, O-Demethyldaunomycin, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of KARMINOMYCIN

 

High impact information on KARMINOMYCIN

 

Chemical compound and disease context of KARMINOMYCIN

 

Biological context of KARMINOMYCIN

 

Anatomical context of KARMINOMYCIN

 

Associations of KARMINOMYCIN with other chemical compounds

 

Gene context of KARMINOMYCIN

  • The difference in the accumulation levels and dynamics and in the intracellular distribution of the free and conjugated DR and CM is likely to underlie the higher cytotoxic activities of the anthracycline conjugates with EGF compared to the free drugs [21].
  • These experiments were confirmed using synthetic polynucleotid template poly(rA)n(dT)12-18 for the Rauscher RT enzyme and poly(dA)n . poly(dT)n for E. coli DNA polymerase I. In our work we have shown that Carminomycin, in contrast to Adriamycin and Daunomycin, possesses a highly specific inhibitory effect on the RT enzyme system [22].
 

Analytical, diagnostic and therapeutic context of KARMINOMYCIN

References

  1. Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer. Rozencweig, M., ten Bokkel Huinink, W., Cavalli, F., Bruntsch, U., Dombernowsky, P., Høst, H., Bramwell, V., Renard, G., Van Glabbeke, M., Decoster, G. J. Clin. Oncol. (1984) [Pubmed]
  2. Cloning and sequencing of a gene encoding carminomycin 4-O-methyltransferase from Streptomyces peucetius and its expression in Escherichia coli. Madduri, K., Torti, F., Colombo, A.L., Hutchinson, C.R. J. Bacteriol. (1993) [Pubmed]
  3. Recent results with clinically used antineoplastic drugs and drug combinations in vivo. Arnold, W., Tanneberger, S., Nowak, C., Naundorf, H. Oncology (1980) [Pubmed]
  4. Mechanism of acute anthracycline cardiotoxicity in isolated rat hearts: carminomycin versus daunomycin. Saman, S., Jacobs, P., Opie, L.H. Cancer Res. (1984) [Pubmed]
  5. Sensitivity of bone marrow hematopoietic colony-forming cells from mice, dogs, and humans to carminomycin, marcellomycin, aclacinomycin A, and N,N-dibenzyldaunorubicin and its relationship to clinical toxicity. Marsh, J.C., Brown, B.J., Nierenburg, M.M. Cancer Res. (1983) [Pubmed]
  6. A phase I and clinical pharmacology study of intravenously administered carminomycin in cancer patients in the United States. Comis, R.L., Issell, B.F., Pittman, K., Ginsberg, S.J., Rudolph, A., Aust, J.C., DiFino, S.M., Tinsley, R.W., Poiesz, B.J., Crooke, S.T. Cancer Res. (1982) [Pubmed]
  7. Acute ultrastructural effects of the antitumor antibiotic carminomycin on nucleoli of rat tissues. Merski, J.A., Daskal, Y., Crooke, S.T., Busch, H. Cancer Res. (1979) [Pubmed]
  8. DNA damage by anthracycline drugs in human leukemia cells. Schwartz, H.S., Kanter, P.M. Cancer Lett. (1981) [Pubmed]
  9. Anthraquinone-induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes. Andersson, B.S., Eksborg, S., Vidal, R.F., Sundberg, M., Carlberg, M. Toxicology (1999) [Pubmed]
  10. Carminomycin. A new anthracycline analog in the treatment of advanced breast cancer. Aboud, A., Yap, H.Y., Esparza, L., Blumenschein, G.R., Hortobagyi, G., Issell, B., Bodey, G.P. Cancer (1984) [Pubmed]
  11. Combination chemotherapy for advanced diffuse large cell lymphoma. The adverse effects of bone marrow invasion, gastrointestinal tract involvement or high bulk disease. Jacobs, P., King, H.S., Dent, D.M. Haematologia (Budap) (1990) [Pubmed]
  12. Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells. Long, B.H., Willis, C.E., Prestayko, A.W., Crooke, S.T. Mol. Pharmacol. (1982) [Pubmed]
  13. Structural basis of anthracycline selectivity for unilamellar phosphatidylcholine vesicles: an equilibrium binding study. Burke, T.G., Tritton, T.R. Biochemistry (1985) [Pubmed]
  14. Pharmacokinetics of carminomycin in dogs and humans. Preliminary report. Reich, S.D., Fandrich, S.E., Finkelstein, T.T., Schurig, J.E., Florczyk, A.P., Comis, R.L., Crooke, S.T. Cancer Chemother. Pharmacol. (1981) [Pubmed]
  15. Optimization of experimental conditions for the preparative displacement chromatography of antitumor anthracycline antibiotics on carboxylic sorbents. Toshchevikova, A.Y., Ezhova, N.M., Pisarev, O.A. Journal of chromatography. A. (2003) [Pubmed]
  16. Partial purification and properties of carminomycin 4-O-methyltransferase from Streptomyces sp. strain C5. Connors, N.C., Strohl, W.R. J. Gen. Microbiol. (1993) [Pubmed]
  17. One-electron reduction of an anthracycline antibiotic carminomycin by a human erythrocyte redox chain. Peskin, A.V., Bartosz, G. FEBS Lett. (1987) [Pubmed]
  18. Effect of carminomycin on the viability of fibroblasts from patients with regular trisomy 21. Rózga, B., Peskin, A.V., Bartosz, G. Free Radic. Res. Commun. (1990) [Pubmed]
  19. Toxic effects of violamycin Bi, carminomycin and daunorubicin on the myocardium of rabbits. Kirchner, E., Güttner, J., Fritsch, R.S., Härtl, A., Hoffmann, H. Acta pharmacologica et toxicologica. (1981) [Pubmed]
  20. Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells in vitro. Dodion, P., Sanders, C., Rombaut, W., Mattelaer, M.A., Rozencweig, M., Stryckmans, P., Kenis, Y. European journal of cancer & clinical oncology. (1987) [Pubmed]
  21. Cytotoxic activity, accumulation, and intracellular distribution of anthracycline antibiotics and their conjugates with the epidermal growth factor in sensitive and resistant MCF-7 cells. Lutsenko, S.V., Feldman, N.B., Gumanov, S.G., Rodina, A.V., Severin, S.E. Biochemistry Mosc. (2000) [Pubmed]
  22. Inhibition of RNA dependent DNA polymerases by anthracycline antibiotics. Bogdány, L., Csányi, E. Neoplasma (1982) [Pubmed]
  23. Analysis of carminomycin in human serum by fluorometric high-performance liquid chromatography. Fandrich, S.E., Pittman, K.A. J. Chromatogr. (1981) [Pubmed]
  24. Pharmacokinetics of carminomycin in man: biweekly schedule vs single dose every three weeks. Weenen, H., Pinedo, H.M., de Planque, M.M., Ten Bokkel Huinink, W.W., McVie, J.G., Lankelma, J. European journal of cancer & clinical oncology. (1984) [Pubmed]
  25. Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study. Bramwell, V.H., Mouridsen, H.T., Mulder, J.H., Somers, R., Van Oosterom, A.T., Santoro, A., Thomas, D., Sylvester, R., Markham, D. European journal of cancer & clinical oncology. (1983) [Pubmed]
 
WikiGenes - Universities